RxDoctor Payments Data

William Lian, MD

Interventional Pain Medicine · Mansfield, TXNPI 1538694336

Payments from drug & device makers

$6,099in general payments, 2019–2025

Across 135 payments — averaging $45.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$2K
  • Nalu Medical, Inc.$730
  • Biotronik NRO, Inc.$403
  • Abbott$243
  • Nevro Corp.$126
  • plus $750 from 16 others
$16in research payments, 2019–2025

Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$16

What the payments were for

  • Travel & lodging$1,86431%
  • Food & beverage$4,23569%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,099 in reported general payments places this provider in the 45th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$335,395
Medicare patients
377
Services billed
3,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,588$54,280
Nurtec OdtRimegepant Sulfate22$47,968
Buprenorphine268$45,050
MovantikNaloxegol Oxalate107$43,766
Xtampza ErOxycodone Myristate69$39,718
Lidocaine286$27,455
Nucynta ErTapentadol Hcl19$16,602
OxycontinOxycodone Hcl26$15,809
Diclofenac Sodium126$13,207
LinzessLinaclotide21$11,559
BelbucaBuprenorphine Hcl16$9,930
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen255$8,800
Pregabalin420$8,280
Gabapentin607$5,907
Naloxone Hcl102$5,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$62$47,96822 claims
AbbVieLinzess$50$11,55921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →